Page 439 - شرور شركات الأدوية

‫ﻣﻼﺣﻈﺎت‬

(7) Bosch X, Esfandiari B, McHenry L. Challenging Medical Ghostwriting
in US Courts. PLoS Med. 2012 Jan 4;9(1):e1001163.

‫ﻣﺎذا ﺑﻌﺪ؟‬

(1) The citation here is, for obvious reasons, ‘personal communica-
tion’. The email from the academic continued: ‘From my perspective, I don’t
think we should be anything but indignant!’.

(2) Vedula SS, Li T, Dickersin K. Differences in Reporting of Analyses
in Internal Company Documents Versus Published Trial Reports: Compar-
isons in Industry-Sponsored Trials in Off-Label Uses of Gabapentin. PLoS
Med. 2013 Jan 29;10(1):e1001378.

(3) Sample, Ian. Big pharma mobilising patients in battle over drugs
trials data. Guardian, 21st July 2013.

(4) http://www.alltrials.net/2013/responses-to-leaked-memo/.
(5) Huser V, Cimino JJ (2013) Linking ClinicalTrials.gov and PubMed
to Track Results of Interventional Human Clinical Trials. PLoS ONE 8(7):
e68409. doi:10.1371/journal.pone.0068409.
(6) Schroll JB, Bero L, Gøtzsche PC. Searching for unpublished data for
Cochrane reviews: cross sectional study. BMJ 2013;346:f2231.
(7) Wieseler B, McGauran N, Kerekes MF, Kaiser T. Access to regulatory
data from the European Medicines Agency: the times they are a-changing.
Syst Rev. 2012 Oct 30;1:50.
(8) Little RJ, D’Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar
JT, et al. The Prevention and Treatment of Missing Data in Clinical Trials.
N Engl J Med. 2012; 367:1355–1360.
(9) Mathieu S, Chan A-W, Ravaud P (2013) Use of Trial Register
Information during the Peer Review Process. PLoS ONE 8(4): e59910.
doi:10.1371/journal.pone.0059910.

439